Biliary tract and liver complications in polycystic kidney disease

Biliary tract and liver complications in polycystic kidney disease

<p>Polycystic liver disease is a well-described manifestation of autosomal dominant polycystic kidney disease (ADPKD). Biliary tract complications are less well-recognised. We report a 50-year single-centre experience of 1,007 patients, which raised a hypothesis that ADPKD is associated with b...

Full description

Bibliographic Details
Main Authors:	Judge, P, Harper, C, Storey, B, Haynes, R, Wilcock, M, Staplin, N, Goldacre, R, Baigent, C, Collier, J, Goldacre, M, Landray, M, Winearls, C, Herrington, W
Format:	Journal article
Published:	American Society for Nephrology 2017

Similar Items

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
by: Storey, B, et al.
Published: (2018)

Neprilysin inhibition in chronic kidney disease.
by: Judge, P, et al.
Published: (2014)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
by: Zhu, P, et al.
Published: (2020)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
by: Staplin, N, et al.
Published: (2016)

Evidence for the prevention and treatment of stroke in dialysis patients
by: Herrington, W, et al.
Published: (2014)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
by: Herrington, W, et al.
Published: (2022)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
by: Herrington, WG, et al.
Published: (2023)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
by: Mayne, K, et al.
Published: (2024)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
by: Haynes, R, et al.
Published: (2018)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
by: Mayne, KM, et al.
Published: (2024)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
by: Herrington, W, et al.
Published: (2018)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
by: Staplin, N, et al.
Published: (2022)

Effect of processing delay and storage conditions on urine albumin-to-creatinine ratio
by: Herrington, W, et al.
Published: (2016)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
by: Herrington, W, et al.
Published: (2016)

Survival after starting renal replacement treatment in patients with autosomal dominant polycystic kidney disease: a single-centre 40-year study.
by: Haynes, R, et al.
Published: (2012)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
by: Mayne, K, et al.
Published: (2023)

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
by: Zhu, D, et al.
Published: (2024)

Chronic kidney disease, heart failure and neprilysin inhibition
by: Haynes, R, et al.
Published: (2019)

Reassuring results with regard to the effect of donor nephrectomy on cardiovascular outcomes.
by: Haynes, R, et al.
Published: (2009)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)
by: Haynes, R, et al.
Published: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
by: Haynes, R, et al.
Published: (2014)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
by: Zhu, P, et al.
Published: (2020)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
by: Staplin, N, et al.
Published: (2023)

Kidney disease trials for the 21st century: innovations in design and conduct
by: Herrington, W, et al.
Published: (2019)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
by: Storey, B, et al.
Published: (2017)

Does prophylactic anticoagulation reduce the risk of femoral tunneled dialysis catheter-related complications?
by: Herrington, W, et al.
Published: (2013)

Use of gel-based separator tubes to stabilise phosphate in mailed blood samples.
by: Herrington, W, et al.
Published: (2015)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
by: Mihaylova, B, et al.
Published: (2019)

Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial
by: Haynes, R, et al.
Published: (2018)

Conventional and genetic evidence on the association between adiposity and CKD
by: Zhu, P, et al.
Published: (2020)

Which cardiovascular risk factors matter in chronic kidney disease?
by: Baigent, C, et al.
Published: (2007)

Elective conversion to sirolimus vs. continued tacrolimus in kidney transplantation (the 3c study): Results of a randomized trial
by: Haynes, R, et al.
Published: (2017)

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
by: Haynes, R, et al.
Published: (2014)

Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study
by: Donovan, K, et al.
Published: (2022)

Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
by: Haynes, R, et al.
Published: (2014)

Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
by: Haynes, R, et al.
Published: (2014)

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
by: Judge, PK, et al.
Published: (2024)

Trends in the Incidence and Recurrence of Inpatient-Treated Spontaneous Pneumothorax, 1968-2016
by: Hallifax, R, et al.
Published: (2018)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
by: Schlackow, I, et al.
Published: (2017)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection
by: Reith, C, et al.
Published: (2017)